Hormone clues behind severe PMS symptoms under investigation

NCT ID NCT07686718

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at whether women with premenstrual dysphoric disorder (PMDD) have different levels of the hormones progesterone and estrogen in the week after ovulation compared to women without PMDD. Researchers will take a single blood sample about 7 days after ovulation and measure these hormone levels. The goal is to better understand the biological basis of PMDD, which could lead to improved diagnosis or treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If differences are found, this could point toward better diagnosis or targeted treatments for PMDD.
What could go wrong
This is a small observational study, not a treatment trial. It may not find clear differences, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

adults of reproductive age who experience menstrual cycles and have a diagnosis of, or symptoms consistent with, Premenstrual Dysphoric Disorder (PMDD) or a control population

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Aged 18-45 years old (adults but less than the typical perimenopausal age so there is not added bias/variable) * Regular menstrual cycles (21-35 days for the last 3 months) * Willing and able to complete a questionnaire (no new clinical diagnosis given) * Use home urine LH test strips to detect ovulation * Attend a single in person on site in Lancaster mid luteal blood test sample appointment (approx 7 days post LH surge) * Provide written informed consent * Have sufficient English language skills to understand the patient information * Be either in Group 1 or group 2 Group 1 (PMDD group ie case group) - self reported prior diagnosis of PMDD made by a healthcare professional (GP, psychiatrist, gynaecologist) Group 2 (Control group ie comparison group) - no prior diagnosis of PMDD made by a healthcare professional and no history of clinically significant premenstrual mood symptoms on screening Exclusion criteria * Current use or use in the last 3 months of hormonal contraception such as the combined oral contraceptive pill, the progestogen only pill, the implant, the injection, hormonal coil (Mirena, Kyleena) or patch/ring. * Current use or use in the last 3 months of any hormone replacement therapy (e.g. combined oestrogen and progesterone, oestrogen and Mirena coil combination, oestrogen alone if had a hysterectomy, or progesterone alone) or GnRH analogues use * On a selective serotonin reuptake inhibitor (SSRI) with a recent initiation or dose change within the last 3 months * Pregnant, breastfeeding or within 3 months post partum * Irregular menstrual cycles (outside the 21-35 day window) * Surgical menopause * Premature ovarian insufficiency * Other endocrine disorders e.g. uncontrolled thyroid disease, high prolactin, cushing's syndrome, polycystic ovarian syndrome) * Regular systemic steroid use or use of other medications known to affect sex hormone within the last 3 months * Severe mental health issues that impair consent or participation * Needle phobic so that venepuncture is intolerable * The use of the emergency contraceptive pill either 3 months prior to the study or during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premenstrual dysphoric disorder (PMDD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lancaster University

    RECRUITING

    Lancaster, Lancashire, LA1 4YW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.